Apeloa Pharmaceutical (000739.SZ) subsidiary receives the registration certificate for Levocarnitine Injection.

Apeloa Pharmaceutical (000739.SZ) announced that its holding subsidiary, Zhejiang Pukangyuyu Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for Levocarnitine Injection issued by the National Medical Products Administration. This drug is used for a series of complications caused by secondary carnitine deficiency in patients with chronic kidney failure undergoing long-term hemodialysis, with clinical manifestations such as cardiomyopathy, skeletal muscle disease, arrhythmia, hyperlipidemia, low blood pressure, and muscle spasms during dialysis. According to relevant data, the market size of Levocarnitine Injection in the Chinese hospital market in 2024 is estimated to be 103 million units, with sales amounting to 965 million yuan. As of the disclosure date of this announcement, the cumulative research and development expenses for Levocarnitine Injection amounted to RMB 3.7629 million.